Articles and Videos
Loading...
December 21, 2021
The Dales Report: InMed Pharmaceuticals – 2022 Looking Bright With Recent Acquisition Of BayMedica
The Dales Report Host Shadd Dales spoke with InMed CEO, Eric A. Adams, about plans for 2022. Excerpt from The Dales Report: Listed on the...
Source: The Dales Report
December 20, 2021
InMed Welcomes the BayMedica Team – Meet Research Scientist Dr. James Craig!
InMed Pharmaceuticals is pleased to welcome the BayMedica team following its acquisition in October 2021. Meet Dr. James Craig, one of our Research Scientists at...
December 15, 2021
InMed Welcomes the BayMedica Team – Welcome Dr. Jim Kealey, VP of Synthetic Biology
InMed Pharmaceuticals is pleased to welcome the BayMedica team following its acquisition in October 2021. Meet Dr. Jim Kealey, our VP of Synthetic Biology. Jim...
Source: Edison TV
December 8, 2021
InMed Welcomes the BayMedica Team! Welcome Dr. Charles Marlowe, VP of Chemistry
InMed Pharmaceuticals is pleased to welcome the BayMedica team following its acquisition in October 2021. Meet Dr. Charles Marlowe, our VP of Chemistry. Chuck talks...
Source: Edison TV
December 1, 2021
InMed Welcomes the BayMedica Team! Meet Philip Barr, VP of Discovery Research
InMed Pharmaceuticals is pleased to welcome to the BayMedica team following its acquisition in October 2021. Meet Philip Barr, our VP of Discovery Research. Phil...
Source: Edison TV
November 30, 2021
InMed’s Pharmaceutical Programs in Epidermolysis Bullosa and Glaucoma and Pharma Partnership Opportunities
In this excerpt from The Dales Report interview with host Shadd Dales, InMed's CEO Eric A. Adams talks about the Company's pharmaceutical programs in Epidermolysis...
Source: The Dales Report